Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner*, Courtney D. DiNardo, Frederick R. Appelbaum, Charles Craddock, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Lucy A. Godley, Robert P. Hasserjian, Richard A. Larson, Ross L. Levine, Yasushi Miyazaki, Dietger Niederwieser, Gert Ossenkoppele, Christoph Röllig, Jorge Sierra, Eytan M. Stein, Martin S. Tallman, Hwei Fang Tien, Jianxiang WangAgnieszka Wierzbowska, Andrew H. Wei, Bob Löwenberg

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

13 Citations (Scopus)

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Original languageEnglish
Pages (from-to)2169-2173
Number of pages5
JournalBlood
Volume144
Issue number21
DOIs
Publication statusPublished - 12 Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 American Society of Hematology

Fingerprint

Dive into the research topics of 'Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations'. Together they form a unique fingerprint.

Cite this